<p>隨着全球市場經歷反彈，標普 500 指數和納斯達克綜合指數創下歷史新高，小型股在温和通脹上升和經濟指標混雜的複雜環境中航行。在這種動態環境中，識別有前景的小型公司需要關注那些具有強大基本面和潛在增長驅動因素的公司，以抵禦更廣泛市場的波動。</p>
<h3>全球十大未被發現的基本面強勁的寶藏股</h3>
<table>
<thead>
<tr>
<th>名稱</th>
<th>債務股本比</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>健康評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>AIC</td>
<td>不適用</td>
<td>26.88%</td>
<td>54.47%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CTCI 先進系統</td>
<td>39.96%</td>
<td>21.96%</td>
<td>24.04%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>先進國際多技術</td>
<td>35.32%</td>
<td>3.62%</td>
<td>1.11%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Saha-Union</td>
<td>0.84%</td>
<td>0.90%</td>
<td>15.45%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Alf Meem Yaa 醫療器械和設備</td>
<td>不適用</td>
<td>17.03%</td>
<td>18.37%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Nofoth 食品產品</td>
<td>不適用</td>
<td>15.75%</td>
<td>27.63%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>洪亮金融</td>
<td>0.07%</td>
<td>6.89%</td>
<td>6.61%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>新加坡投資與金融</td>
<td>0.29%</td>
<td>9.07%</td>
<td>12.24%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Mechema 化學國際</td>
<td>55.74%</td>
<td>-4.23%</td>
<td>-5.72%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>國家旅遊與酒店公司</td>
<td>19.25%</td>
<td>0.67%</td>
<td>4.89%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們全球未被發現的基本面強勁的寶藏股篩選器中的 3161 只股票的完整列表。</p>
<p>在這裏，我們重點介紹我們獨家的篩選器中的幾隻最愛。</p>
<h2>山東百龍創園生物科技（SHSE:605016）</h2>
<p><strong>Simply Wall St 價值評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 山東百龍創園生物科技有限公司在生物技術領域運營，市值為 88 億人民幣。</p>
<p><strong>運營：</strong> 該公司主要通過其生物技術業務產生收入。其市值約為 88 億人民幣，顯示出其在該領域的重要地位。</p>
<p>山東百龍創園生物科技作為生物技術領域的靈活參與者，過去一年顯示出 35.3% 的可觀盈利增長，超越了面臨下滑的行業同行。該公司的交易價格低於其估計的公允價值 7.1%，暗示潛在的低估。公司現金多於總債務，且債務股本比在五年內從 9% 降至 8.5%，財務健康狀況似乎穩健。最近的季度業績顯示強勁表現，銷售額從 2.52 億人民幣攀升至 3.13 億人民幣，淨收入從 5400 萬人民幣上升至 8100 萬人民幣，同比增加。</p>
<ul>
<li>在我們的健康報告中更詳細地瞭解山東百龍創園生物科技的潛力。</li>
<li>通過我們的歷史報告深入瞭解山東百龍創園生物科技的過去趨勢和表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c11836c5-6786-40b5-a4cc-a935a1cc2ed1/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c11836c5-6786-40b5-a4cc-a935a1cc2ed1/chart/debt-equity-history-analysis"/></p>
<p>截至 2025 年 7 月 SHSE:605016 的債務股本比</p>
<h2>大連華鋭重工集團（SZSE:002204）</h2>
<p><strong>Simply Wall St 價值評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> 大連華鋭重工集團有限公司在特種設備製造領域運營，市值約為 115.7 億人民幣。</p>
<p><strong>運營：</strong> 該公司從其特種設備製造部門產生了 146 億人民幣的收入。</p>
<p>大連華鋭重工集團在過去一年顯示出 36.6% 的可觀盈利增長，超越了機械行業的 1%。儘管其債務股本比在五年內從 7.6% 上升至 22.3%，但它持有的現金超過總債務，確保了財務穩定。公司的市盈率為 23.8 倍，相較於中國市場的 39.6 倍，暗示潛在的低估。最近的發展包括 2024 年每股派息 0.50 元的增加，以及在今年 4 月的股東大會上批准的章程修訂。</p>
<ul>
<li>在這裏深入瞭解大連華鋭重工集團的完整分析健康報告。</li>
<li>通過我們的詳細歷史業績報告評估大連華鋭重工集團的過去表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2d9ed701-39b6-4e8d-b30c-466188b1a02a/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2d9ed701-39b6-4e8d-b30c-466188b1a02a/chart/earnings-and-revenue-growth"/></p>
<p>截至 2025 年 7 月 SZSE:002204 的盈利和收入增長</p>
<h2>北京 SDL 科技有限公司（SZSE:002658）</h2>
<p><strong>Simply Wall St 價值評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 北京 SDL 科技有限公司及其子公司開發和銷售環境監測設備和解決方案，市場價值為 53.8 億人民幣。</p>
<p><strong>運營：</strong> 該公司的收入主要來自環境監測設備和解決方案的銷售。其財務表現以淨利潤率為亮點，反映出其相對於收入有效管理成本的能力。</p>
<p>北京 SDL 科技在過去一年顯示出 10% 的顯著盈利增長，超越了電子行業的 2.9%。該公司的債務股本比在五年內顯著下降，從 21.5% 降至僅 0.07%，展示出強大的財務紀律。其市盈率為 32 倍，相較於中國市場的平均水平 39.6 倍，具有吸引力。最近的報告顯示盈利能力的扭轉，淨收入達到 1000 萬人民幣，而去年則出現虧損，銷售額從 2.31 億人民幣攀升至 2.54 億人民幣，成為今年第一季度的亮點。</p>
<ul>
<li>在這份健康報告中解鎖我們對北京 SDL 科技有限公司股票分析的全面見解。</li>
<li>通過檢查我們的歷史報告瞭解北京 SDL 科技有限公司的業績記錄。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8ae9fbfc-676f-4990-99e4-6f8ba838416e/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8ae9fbfc-676f-4990-99e4-6f8ba838416e/chart/debt-equity-history-analysis"/></p>
<p>截至 2025 年 7 月 SZSE:002658 的債務股本比</p>
<h2>讓它發生</h2>
<ul>
<li>在這裏深入瞭解我們完整的 3161 個全球未被發現的基本面強勁的投資機會。</li>
<li>已經擁有這些公司的股票？將您的投資組合鏈接到 Simply Wall St，並獲取有關您股票的新警示信息。</li>
<li>免費使用 Simply Wall St 的應用程序簡化您的投資策略，並受益於對全球各地股票的廣泛研究。</li>
</ul>
<h2>準備好嘗試不同的方法了嗎？</h2>
<ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司來充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
<p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成購買或出售任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>

百龍創園

<p>隨着全球市場的反彈，小型股在温和的通脹和混合的經濟指標中表現出色。山東百龍創園生物科技顯示出 35.3% 的可觀盈利增長，並且其交易價格低於估算的公允價值，表明可能被低估。大連華瑞重工集團也展現出 36.6% 的強勁盈利增長和良好的市盈率。同時，北京 SDL 科技實現了盈利能力的顯著扭轉，淨收入達到 1000 萬元人民幣。這些公司被認為是具有強大基本面的有前景的小型股投資</p>

<p>As global markets experience a rally with key indices like the S&amp;P 500 and Nasdaq Composite reaching all-time highs, small-cap stocks are navigating a complex landscape marked by modest inflation upticks and mixed economic indicators. In this dynamic environment, identifying promising small-cap companies involves looking for those with strong fundamentals and potential growth drivers that can withstand broader market fluctuations.</p>
<div class="lb-trans"><p>隨着全球市場經歷反彈，標普 500 指數和納斯達克綜合指數創下歷史新高，小型股在温和通脹上升和經濟指標混雜的複雜環境中航行。在這種動態環境中，識別有前景的小型公司需要關注那些具有強大基本面和潛在增長驅動因素的公司，以抵禦更廣泛市場的波動。</p>
</div><h3>Top 10 Undiscovered Gems With Strong Fundamentals Globally</h3>
<div class="lb-trans"><h3>全球十大未被發現的基本面強勁的寶藏股</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Debt To Equity</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Health Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>AIC</td>
<td>NA</td>
<td>26.88%</td>
<td>54.47%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CTCI Advanced Systems</td>
<td>39.96%</td>
<td>21.96%</td>
<td>24.04%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Advanced International Multitech</td>
<td>35.32%</td>
<td>3.62%</td>
<td>1.11%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Saha-Union</td>
<td>0.84%</td>
<td>0.90%</td>
<td>15.45%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Alf Meem Yaa for Medical Supplies and Equipment</td>
<td>NA</td>
<td>17.03%</td>
<td>18.37%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Nofoth Food Products</td>
<td>NA</td>
<td>15.75%</td>
<td>27.63%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Hong Leong Finance</td>
<td>0.07%</td>
<td>6.89%</td>
<td>6.61%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Sing Investments &amp; Finance</td>
<td>0.29%</td>
<td>9.07%</td>
<td>12.24%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Mechema Chemicals International</td>
<td>55.74%</td>
<td>-4.23%</td>
<td>-5.72%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>National Corporation for Tourism and Hotels</td>
<td>19.25%</td>
<td>0.67%</td>
<td>4.89%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名稱</th>
<th>債務股本比</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>健康評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>AIC</td>
<td>不適用</td>
<td>26.88%</td>
<td>54.47%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CTCI 先進系統</td>
<td>39.96%</td>
<td>21.96%</td>
<td>24.04%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>先進國際多技術</td>
<td>35.32%</td>
<td>3.62%</td>
<td>1.11%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Saha-Union</td>
<td>0.84%</td>
<td>0.90%</td>
<td>15.45%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Alf Meem Yaa 醫療器械和設備</td>
<td>不適用</td>
<td>17.03%</td>
<td>18.37%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Nofoth 食品產品</td>
<td>不適用</td>
<td>15.75%</td>
<td>27.63%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>洪亮金融</td>
<td>0.07%</td>
<td>6.89%</td>
<td>6.61%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>新加坡投資與金融</td>
<td>0.29%</td>
<td>9.07%</td>
<td>12.24%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Mechema 化學國際</td>
<td>55.74%</td>
<td>-4.23%</td>
<td>-5.72%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>國家旅遊與酒店公司</td>
<td>19.25%</td>
<td>0.67%</td>
<td>4.89%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 3161 stocks from our Global Undiscovered Gems With Strong Fundamentals screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們全球未被發現的基本面強勁的寶藏股篩選器中的 3161 只股票的完整列表。</p>
</div><p>Below we spotlight a couple of our favorites from our exclusive screener.</p>
<div class="lb-trans"><p>在這裏，我們重點介紹我們獨家的篩選器中的幾隻最愛。</p>
</div><h2>Shandong Bailong Chuangyuan Bio-Tech (SHSE:605016)</h2>
<div class="lb-trans"><h2>山東百龍創園生物科技（SHSE:605016）</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 價值評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. operates in the biotechnology sector and has a market capitalization of CN¥8.80 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 山東百龍創園生物科技有限公司在生物技術領域運營，市值為 88 億人民幣。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from its biotechnology operations. It has a market capitalization of approximately CN¥8.80 billion, indicating its significant presence in the sector.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司主要通過其生物技術業務產生收入。其市值約為 88 億人民幣，顯示出其在該領域的重要地位。</p>
</div><p>Shandong Bailong Chuangyuan Bio-Tech, a nimble player in the bio-tech sector, has shown impressive earnings growth of 35.3% over the past year, outpacing its industry peers who faced a downturn. The company trades at 7.1% below its estimated fair value, suggesting potential undervaluation. With more cash than total debt and a reduced debt-to-equity ratio from 9% to 8.5% over five years, financial health seems robust. Recent quarterly results highlight strong performance with sales climbing to CNY 313 million from CNY 252 million and net income rising to CNY 81 million from CNY 54 million year-on-year.</p>
<div class="lb-trans"><p>山東百龍創園生物科技作為生物技術領域的靈活參與者，過去一年顯示出 35.3% 的可觀盈利增長，超越了面臨下滑的行業同行。該公司的交易價格低於其估計的公允價值 7.1%，暗示潛在的低估。公司現金多於總債務，且債務股本比在五年內從 9% 降至 8.5%，財務健康狀況似乎穩健。最近的季度業績顯示強勁表現，銷售額從 2.52 億人民幣攀升至 3.13 億人民幣，淨收入從 5400 萬人民幣上升至 8100 萬人民幣，同比增加。</p>
</div><ul>
<li>Take a closer look at Shandong Bailong Chuangyuan Bio-Tech's potential here in our health report.</li>
<li>Gain insights into Shandong Bailong Chuangyuan Bio-Tech's past trends and performance with our Past report.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我們的健康報告中更詳細地瞭解山東百龍創園生物科技的潛力。</li>
<li>通過我們的歷史報告深入瞭解山東百龍創園生物科技的過去趨勢和表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c11836c5-6786-40b5-a4cc-a935a1cc2ed1/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/c11836c5-6786-40b5-a4cc-a935a1cc2ed1/chart/debt-equity-history-analysis"/></p>
<p>SHSE:605016 Debt to Equity as at Jul 2025</p>
<div class="lb-trans"><p>截至 2025 年 7 月 SHSE:605016 的債務股本比</p>
</div><h2>Dalian Huarui Heavy Industry Group (SZSE:002204)</h2>
<div class="lb-trans"><h2>大連華鋭重工集團（SZSE:002204）</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 價值評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Dalian Huarui Heavy Industry Group Co., Ltd. operates in the special-purpose equipment manufacturing sector and has a market capitalization of approximately CN¥11.57 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 大連華鋭重工集團有限公司在特種設備製造領域運營，市值約為 115.7 億人民幣。</p>
</div><p><strong>Operations:</strong> The company generated revenue of CN¥14.60 billion from its special-purpose equipment manufacturing segment.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司從其特種設備製造部門產生了 146 億人民幣的收入。</p>
</div><p>Dalian Huarui Heavy Industry Group has shown impressive earnings growth of 36.6% over the past year, outpacing the Machinery industry's 1%. Despite a rise in its debt to equity ratio from 7.6% to 22.3% over five years, it holds more cash than total debt, ensuring financial stability. The company's price-to-earnings ratio stands at a favorable 23.8x compared to the CN market's 39.6x, suggesting potential undervaluation. Recent developments include a dividend increase with CNY 0.50 per share for 2024 and amendments to its articles of association approved during their AGM in April this year.</p>
<div class="lb-trans"><p>大連華鋭重工集團在過去一年顯示出 36.6% 的可觀盈利增長，超越了機械行業的 1%。儘管其債務股本比在五年內從 7.6% 上升至 22.3%，但它持有的現金超過總債務，確保了財務穩定。公司的市盈率為 23.8 倍，相較於中國市場的 39.6 倍，暗示潛在的低估。最近的發展包括 2024 年每股派息 0.50 元的增加，以及在今年 4 月的股東大會上批准的章程修訂。</p>
</div><ul>
<li>Delve into the full analysis health report here for a deeper understanding of Dalian Huarui Heavy Industry Group.</li>
<li>Assess Dalian Huarui Heavy Industry Group's past performance with our detailed historical performance reports.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏深入瞭解大連華鋭重工集團的完整分析健康報告。</li>
<li>通過我們的詳細歷史業績報告評估大連華鋭重工集團的過去表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2d9ed701-39b6-4e8d-b30c-466188b1a02a/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/2d9ed701-39b6-4e8d-b30c-466188b1a02a/chart/earnings-and-revenue-growth"/></p>
<p>SZSE:002204 Earnings and Revenue Growth as at Jul 2025</p>
<div class="lb-trans"><p>截至 2025 年 7 月 SZSE:002204 的盈利和收入增長</p>
</div><h2>Beijing SDL TechnologyLtd (SZSE:002658)</h2>
<div class="lb-trans"><h2>北京 SDL 科技有限公司（SZSE:002658）</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 價值評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Beijing SDL Technology Co., Ltd. and its subsidiaries develop and sell environmental monitoring equipment and solutions both in China and internationally, with a market cap of CN¥5.38 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 北京 SDL 科技有限公司及其子公司開發和銷售環境監測設備和解決方案，市場價值為 53.8 億人民幣。</p>
</div><p><strong>Operations:</strong> The company's revenue primarily comes from the sale of environmental monitoring equipment and solutions. Its financial performance is highlighted by a net profit margin that reflects its ability to manage costs effectively relative to its revenue.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司的收入主要來自環境監測設備和解決方案的銷售。其財務表現以淨利潤率為亮點，反映出其相對於收入有效管理成本的能力。</p>
</div><p>Beijing SDL Technology has been making waves with a notable earnings growth of 10% over the past year, outpacing the electronic industry's 2.9%. The company's debt to equity ratio impressively dropped from 21.5% to just 0.07% in five years, showcasing strong financial discipline. Its price-to-earnings ratio stands at 32x, which is attractive compared to the CN market's average of 39.6x. Recent reports highlight a turnaround in profitability, with net income reaching CNY 10 million versus a loss last year and sales climbing from CNY 231 million to CNY 254 million for Q1 of this year.</p>
<div class="lb-trans"><p>北京 SDL 科技在過去一年顯示出 10% 的顯著盈利增長，超越了電子行業的 2.9%。該公司的債務股本比在五年內顯著下降，從 21.5% 降至僅 0.07%，展示出強大的財務紀律。其市盈率為 32 倍，相較於中國市場的平均水平 39.6 倍，具有吸引力。最近的報告顯示盈利能力的扭轉，淨收入達到 1000 萬人民幣，而去年則出現虧損，銷售額從 2.31 億人民幣攀升至 2.54 億人民幣，成為今年第一季度的亮點。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of Beijing SDL TechnologyLtd stock in this health report.</li>
<li>Understand Beijing SDL TechnologyLtd's track record by examining our Past report.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這份健康報告中解鎖我們對北京 SDL 科技有限公司股票分析的全面見解。</li>
<li>通過檢查我們的歷史報告瞭解北京 SDL 科技有限公司的業績記錄。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8ae9fbfc-676f-4990-99e4-6f8ba838416e/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/8ae9fbfc-676f-4990-99e4-6f8ba838416e/chart/debt-equity-history-analysis"/></p>
<p>SZSE:002658 Debt to Equity as at Jul 2025</p>
<div class="lb-trans"><p>截至 2025 年 7 月 SZSE:002658 的債務股本比</p>
</div><h2>Make It Happen</h2>
<div class="lb-trans"><h2>讓它發生</h2>
</div><ul>
<li>Delve into our full catalog of 3161 Global Undiscovered Gems With Strong Fundamentals here.</li>
<li>Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.</li>
<li>Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏深入瞭解我們完整的 3161 個全球未被發現的基本面強勁的投資機會。</li>
<li>已經擁有這些公司的股票？將您的投資組合鏈接到 Simply Wall St，並獲取有關您股票的新警示信息。</li>
<li>免費使用 Simply Wall St 的應用程序簡化您的投資策略，並受益於對全球各地股票的廣泛研究。</li>
</ul>
</div><h2>Ready For A Different Approach?</h2>
<div class="lb-trans"><h2>準備好嘗試不同的方法了嗎？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司來充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成購買或出售任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div>

探索山東百龍創園生物科技及全球市場中兩個有前景的小盤股